Abaloparatide injection for preventing fractures in postmenopausal women
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a daily injection called abaloparatide, which helps strengthen bones and reduce the chance of breaking a bone. It is for postmenopausal women with osteoporosis who are at higher risk of fractures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 50 and 85 years old, have gone through menopause, and can walk without help.
- Your bone density test (DXA) shows low bone mass, with a T-score between -2.5 and -5.0 at the spine or hip.
- You have at least one of these risk factors for broken bones: past fracture from a minor fall, a family history of hip fracture, age 70 or older, low body weight, or current smoking.
- You have not taken certain osteoporosis medications recently, and you don't have other bone diseases or active kidney stones.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medication called SAL056 to strengthen bones and prevent fractures in postmenopausal women with osteoporosis. Researchers want to find the best dose and how often to give it.
This study tests a new version of a medicine called abaloparatide (used for bone health) to see if it works the same as the approved version (Tymlos). It is for healthy adults aged 40–65 who are willing to stay at the clinic for a few days and have blood tests.
This study tests how a bone-strengthening medication called Abaloparatide affects the quality of bones in your lower spine. Researchers will use imaging scans to see if the medication helps improve bone strength in people with osteoporosis who also have spine wear-and-tear.
This study tests a daily injection that may help heal broken pelvic or leg bones faster in people with certain health conditions like diabetes or smoking. It is for adults 50 and older who have had a low-energy fracture.
This trial tests teriparatide (a hormone-like bone medicine) to improve bone health in people with advanced chronic kidney disease who are at risk for weak, low-turnover bone. It may help by changing how quickly your bones break down and rebuild.
This study tests whether giving teriparatide (a daily injection that helps build bone) at different times of day makes it work better for women with postmenopausal osteoporosis and very low bone density. If you qualify, you might get the medicine either in the morning or evening, and researchers will track how your bone density changes.
Hear when a new Postmenopausal Women With Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.